At a glance
- Originator Novartis
- Class Antihypertensives
- Mechanism of Action Endothelin B receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Hypertension
Most Recent Events
- 22 May 2001 Profile reviewed but no significant changes made
- 18 Nov 1998 No-Development-Reported for Hypertension in USA (Unknown route)
- 05 Feb 1996 New profile